Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.07% |
| 2 | Technology | 14.35% |
| 3 | Financials | 11.23% |
| 4 | Consumer Discretionary | 9.93% |
| 5 | Real Estate | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Farmers & Merchants Bancorp
FMAO
$486M
| $1.05M | ﹤0.01% |
36,200
+11,900
| +49% | +$357K |
|
|
EV
2652
DELISTED
Eaton Vance Corp.
EV
| $1.05M | ﹤0.01% |
24,300
-1,126,800
| -98% | -$46M |
|
2653
NWPX Infrastructure Inc
NWPX
$1.12B
| $1.05M | ﹤0.01% |
40,600
-23,200
| -36% | -$575K |
|
|
ADXS
2654
DELISTED
Advaxis Inc
ADXS
| $1.05M | ﹤0.01% |
501,000
+295,444
| +144% | +$936K |
|
2655
MakeMyTrip
MMYT
$5.72B
| $1.04M | ﹤0.01% |
42,153
-18,700
| -31% | -$473K |
|
|
MGI
2656
DELISTED
MoneyGram International, Inc. New
MGI
| $1.04M | ﹤0.01% |
423,028
-50,472
| -11% | -$113K |
|
2657
Jefferies Financial Group
JEF
$12.7B
| $1.04M | ﹤0.01% |
+60,648
| New | +$1.04M |
|
2658
FRP Holdings
FRPH
$425M
| $1.04M | ﹤0.01% |
37,400
-11,800
| -24% | -$291K |
|
2659
HUTCHMED
HCM
$2.1B
| $1.04M | ﹤0.01% |
47,400
+3,700
| +8% | +$106K |
|
2660
Moleculin Biotech
MBRX
$4.51M
| $1.04M | ﹤0.01% |
371
+301
| +430% | +$818K |
|
|
LONE
2661
DELISTED
Lonestar Resources US Inc. Class A Common Stock
LONE
| $1.04M | ﹤0.01% |
454,271
-217,029
| -32% | -$736K |
|
|
SLCT
2662
DELISTED
Select Bancorp, Inc.
SLCT
| $1.04M | ﹤0.01% |
90,714
+14,614
| +19% | +$169K |
|
|
USDP
2663
DELISTED
USD PARTNERS LP
USDP
| $1.04M | ﹤0.01% |
91,800
+30,300
| +49% | +$331K |
|
2664
AMCON Distributing
DIT
$66.4M
| $1.03M | ﹤0.01% |
16,185
+135
| +0.8% | +$8.4K |
|
2665
BGSF Inc
BGSF
$59.9M
| $1.03M | ﹤0.01% |
54,600
-38,400
| -41% | -$778K |
|
|
SDRL
2666
DELISTED
Seadrill Limited Common Stock
SDRL
| $1.03M | ﹤0.01% |
247,900
+227,647
| +1,124% | +$1.5M |
|
|
CDTX
2667
DELISTED
Cidara Therapeutics
CDTX
| $1.03M | ﹤0.01% |
30,537
+10,700
| +54% | +$445K |
|
|
UBP
2668
DELISTED
Urstadt Biddle Properties Inc.
UBP
| $1.02M | ﹤0.01% |
59,900
+4,200
| +8% | +$72.4K |
|
2669
Beasley Broadcasting Group
BBGI
$41.6M
| $1.02M | ﹤0.01% |
15,775
+3,385
| +27% | +$239K |
|
|
SMTA
2670
DELISTED
Spirit MTA REIT Common Shares of Beneficial Interest
SMTA
| $1.02M | ﹤0.01% |
+121,823
| New | +$897K |
|
|
ENBL
2671
DELISTED
ENABLE MIDSTREAM PARTNERS, LP
ENBL
| $1.01M | ﹤0.01% |
73,892
-110,008
| -60% | -$1.49M |
|
2672
State Street SPDR Portfolio S&P 500 Growth ETF
SPYG
$55.3B
| $1.01M | ﹤0.01% |
+26,100
| New | +$991K |
|
2673
PJT Partners
PJT
$4.48B
| $1.01M | ﹤0.01% |
24,900
-225,850
| -90% | -$9.21M |
|
|
ASCMA
2674
DELISTED
Ascent Capital Group, Inc. Series A
ASCMA
| $1.01M | ﹤0.01% |
932,307
+3,713
| +0.4% | +$3.37K |
|
|
ALIM
2675
DELISTED
Alimera Sciences
ALIM
| $1M | ﹤0.01% |
75,227
+8,694
| +13% | +$122K |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.